KPTI

Karyopharm Therapeutics Inc

KPTI, USA

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

https://www.karyopharm.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
KPTI
stock
KPTI

Breakouts Watch: Is WBTN stock a contrarian buy - July 2025 Momentum & Fast Moving Market Watchlists moha.gov.vn

Read more →
KPTI
stock
KPTI

Momentum Shift: Will KPTI stock benefit from AI adoption - July 2025 Reactions & Risk Controlled Stock Pick Alerts moha.gov.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$14.6667

Analyst Picks

Strong Buy

2

Buy

3

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bearish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-0.22

Low 1

High 3

Return on Equity (ROE)

-

Low

12.30 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-34.42 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-13.30 %

Low 5%

High 15%

Investors

* Institutions hold a combined 65.49% of the total shares of Karyopharm Therapeutics Inc

1.

T. Rowe Price Investment Management,Inc.

(8.4044%)

since

2025/06/30

2.

Vanguard Group Inc

(5.9768%)

since

2025/06/30

3.

T. Rowe Price Small-Cap Value

(5.1349%)

since

2025/07/31

4.

Adage Capital Partners Gp LLC

(4.8588%)

since

2025/06/30

5.

T. Rowe Price U.S. SC Value Eq Tr-D

(3.0408%)

since

2025/06/30

6.

Eversept Partners, LLC

(2.9656%)

since

2025/06/30

7.

JPMorgan Chase & Co

(2.9574%)

since

2025/06/30

8.

BlackRock Inc

(2.729%)

since

2025/06/30

9.

Vanguard Total Stock Mkt Idx Inv

(2.5743%)

since

2025/07/31

10.

Citadel Advisors Llc

(2.3847%)

since

2025/06/30

11.

Palo Alto Investors, LLC

(2.1671%)

since

2025/06/30

12.

Bank of America Corp

(1.9436%)

since

2025/06/30

13.

UBS Group AG

(1.8671%)

since

2025/06/30

14.

Catalio Capital Management, LP

(1.6839%)

since

2025/06/30

15.

Avidity Partners Management LP

(1.5519%)

since

2025/06/30

16.

Vanguard Explorer Inv

(1.5439%)

since

2025/06/30

17.

Marshall Wace Asset Management Ltd

(1.4813%)

since

2025/06/30

18.

Goldman Sachs Group Inc

(1.2617%)

since

2025/06/30

19.

CAM Group Holding A/S

(1.1532%)

since

2025/06/30

20.

C WorldWide Healthcare Select 1A

(1.1532%)

since

2025/07/31

21.

Group One Trading, LP

(1.129%)

since

2025/06/30

22.

Geode Capital Management, LLC

(1.0591%)

since

2025/06/30

23.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9309%)

since

2025/07/31

24.

Silverback Aset Management LLC

(0.8073%)

since

2025/06/30

25.

Renaissance Technologies Corp

(0.759%)

since

2025/06/30

26.

Altium Capital Management, LP

(0.5689%)

since

2025/03/31

27.

BlackRock Advantage Small Cap Core Instl

(0.5376%)

since

2025/07/31

28.

Fidelity Extended Market Index

(0.5231%)

since

2025/07/31

29.

Macquarie Healthcare I

(0.3844%)

since

2025/07/31

30.

Bridgeway Ultra-Small Company

(0.321%)

since

2025/06/30

31.

Vanguard VIF Small Co Gr

(0.2796%)

since

2025/06/30

32.

Extended Equity Market Fund K

(0.2316%)

since

2025/06/30

33.

T. Rowe Price U.S. Equities Tr

(0.2038%)

since

2025/06/30

34.

iShares Micro-Cap ETF

(0.2026%)

since

2025/08/31

35.

Fidelity Total Market Index

(0.1706%)

since

2025/07/31

36.

Goldman Sachs Absolute Ret Trckr Instl

(0.1598%)

since

2025/06/30

37.

Blackrock Russell 2000 Alpha Tilts Fd A

(0.1581%)

since

2025/06/30

38.

Fidelity Series Total Market Index

(0.142%)

since

2025/07/31

39.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.0636%)

since

2024/12/31

40.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0291%)

since

2024/12/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2025-09-30

EPS Actual

-3.82

EPS Estimate

-2.21

EPS Difference

-1.61

Surprise Percent

-72.8507%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(2)
Momentum
No Momentum(3)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(1.5)
Value
Overpriced(2)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.